

Pharmacotherapy Research for the Treatment of *In-Utero* Substance Exposed Neonates: *Advances and Future Directions*

Agenda

Day 1: Thursday, March 8, 2007

8:00am **Registration**

8:30am **Welcome and Introductions:**

Steven Oversby, Psy. D.

Frank Vocci, Ph.D.

The Public Health Scope of In-Utero Substance Exposure

Ivan Montoya, M.D., M.P.H.

NIDA Longitudinal Cohort Studies of Prenatal Drug Exposure

Description and Progress

Vince Smeriglio, Ph.D.

***In-Utero* Substance Exposure and the DPMC Portfolio**

Jamie Biswas, Ph.D.

9:30 am **Overview of *In-Utero* Substance Exposure**

Loretta Finnegan, M.D.

10:15 am *Break*

10:30 am-12:15 pm **Pharmacotherapy of *In-utero* Opioid Exposed Infants**

Session Chair: *Karol Kaltenbach, Ph.D.*

Maternal and Fetal Neurophysiology and Opioid Exposure

Lauren Jansson, M.D.

Opiate Agonists for the Treatment of NAS

Karol Kaltenbach, Ph.D.

Morphine/Barbiturates Treatment in neonates

Gabriele Fischer, M.D.

Use of DTO and Phenobarbital for the Treatment of Neonatal Opiate Withdrawal in the Term Infant

Mara Coyle, M.D.

12:15pm-1:30pm **Lunch (Doubletree Hotel)**

1:30 am-3:00 pm **Pharmacotherapy of *In-utero* Opioid Exposed Infants:
(continued)**
Session Chair: *Karol Kaltenbach, Ph.D.*

**Clonidine an Adjunct Therapy for the Treatment of
NAS**
Estelle Gauda, M.D.

Trial of Buprenorphine for the Treatment of NAS
Michelle Ehrlich, M.D. & Walter Kraft, M.D.

The MOTHER Study & the Treatment of NAS
Hendree Jones, Ph.D.

Discussion
Karol Kaltenbach, Ph.D.

3:00 pm - 3:15 pm **Break**

3:15 pm – 5:00pm ***In-utero* Exposure to Alcohol**
Session Chair: Laurie Foudin, Ph.D.

Overview: Fetal Alcohol Spectrum Disorders
Michael E. Charness, M.D.

**Prevention of Alcohol-Induced Damage in Fetal Alcohol
Syndrome**
Cathy Spong, M.D

Discussion
Laurie Foudin, Ph.D.

5:00pm **Adjourn**